ClinicalTrials.gg

Program

VH4770359

A development code.

In GlaxoSmithKline's pipeline, Capsid protein inhibitor. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.

Furthest: phase 1, since Apr 6, 20261 company-led study, 1 open or runningNext primary completion: May 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Apr 6, 2026Apr 6, 2026May 5, 2027phase 1 · NCT07525544
  • Named in GlaxoSmithKline’s own pipeline as VH4770359, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 6, 2026First study: phase 1 study in HIV InfectionsFirst studyNCT07525544 · 214 planned · United States

Ahead

  1. May 5, 2027Primary completion: phase 1 study in HIV InfectionsNCT07525544

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Capsid protein inhibitor”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07525544HIV Infections · United States1RecruitingMay 5, 2027214

How it is read

Names in the registry

  • “VH4770359”, 1 entry

Codes read as this program: VH4770359.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.